Polaris Group Past Earnings Performance
Past criteria checks 0/6
Polaris Group's earnings have been declining at an average annual rate of -5.3%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 34.1% per year.
Key information
-5.3%
Earnings growth rate
23.4%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 34.1% |
| Return on equity | -16.1% |
| Net Margin | -37,729.4% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Polaris Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 4 | -1,321 | 257 | 1,320 |
| 30 Jun 23 | 3 | -1,202 | 240 | 1,147 |
| 31 Mar 23 | 5 | -1,176 | 238 | 1,036 |
| 31 Dec 22 | 6 | -1,150 | 235 | 924 |
| 30 Sep 22 | 11 | -1,022 | 228 | 778 |
| 30 Jun 22 | 13 | -941 | 210 | 689 |
| 31 Mar 22 | 14 | -841 | 195 | 622 |
| 31 Dec 21 | 15 | -740 | 180 | 554 |
| 30 Sep 21 | 14 | -744 | 164 | 562 |
| 30 Jun 21 | 17 | -683 | 158 | 541 |
| 31 Mar 21 | 13 | -672 | 147 | 543 |
| 31 Dec 20 | 9 | -660 | 135 | 545 |
| 30 Sep 20 | 5 | -713 | 141 | 583 |
| 30 Jun 20 | 0 | -766 | 146 | 621 |
| 31 Mar 20 | 0 | -798 | 154 | 627 |
| 31 Dec 19 | 0 | -830 | 162 | 633 |
| 30 Sep 19 | 0 | -887 | 183 | 673 |
| 30 Jun 19 | 0 | -944 | 203 | 714 |
| 31 Mar 19 | 0 | -988 | 213 | 753 |
| 31 Dec 18 | 0 | -1,032 | 222 | 792 |
| 30 Sep 18 | 0 | -997 | 217 | 750 |
| 30 Jun 18 | 0 | -961 | 213 | 707 |
| 31 Mar 18 | 0 | -930 | 212 | 670 |
| 31 Dec 17 | 0 | -898 | 211 | 633 |
| 30 Sep 17 | 0 | -895 | 214 | 634 |
| 30 Jun 17 | 0 | -891 | 218 | 635 |
| 31 Mar 17 | 0 | -937 | 234 | 666 |
| 31 Dec 16 | 0 | -982 | 250 | 698 |
| 30 Sep 16 | 0 | -1,019 | 275 | 742 |
| 30 Jun 16 | 0 | -1,056 | 300 | 787 |
| 31 Mar 16 | 0 | -1,032 | 298 | 830 |
| 31 Dec 15 | 0 | -1,008 | 295 | 873 |
| 30 Sep 15 | 0 | -971 | 270 | 867 |
| 30 Jun 15 | 0 | -935 | 245 | 861 |
| 31 Mar 15 | 0 | -877 | 219 | 795 |
| 31 Dec 14 | 0 | -820 | 193 | 728 |
Quality Earnings: 6550 is currently unprofitable.
Growing Profit Margin: 6550 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6550 is unprofitable, and losses have increased over the past 5 years at a rate of 5.3% per year.
Accelerating Growth: Unable to compare 6550's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6550 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.8%).
Return on Equity
High ROE: 6550 has a negative Return on Equity (-16.14%), as it is currently unprofitable.